Crossmark

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Crossref DOI link: https://doi.org/10.1186/s13195-019-0492-1

Published Online: 2019-05-01

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Hong, Yun Jeong http://orcid.org/0000-0002-4996-4981
Han, Hyun Jeong

Youn, Young Chul

Park, Kyung Won

Yang, Dong Won

Kim, SangYun

Kim, Hwa Jung

Kim, Ji Eun

Lee, Jae-Hong
Funding

Funding for this research was provided by:

Asan Institute for Life Sciences, Asan Medical Center (2014-0576)

Eisai Korea
License Information

Text and Data Mining valid from 2019-05-01
More Information

Article History

Received: 10 December 2018

Accepted: 9 April 2019

First Online: 1 May 2019

Ethics approval and consent to participate

: The study protocol and informed consent form were reviewed and approved by the institutional review board of each center. The study was conducted in accordance with the Declaration of Helsinki and principles of Good Clinical Practice.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below